Clinical Trials Logo

Recurrent High-grade Glioma clinical trials

View clinical trials related to Recurrent High-grade Glioma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06126744 Not yet recruiting - Clinical trials for Recurrent High Grade Glioma

Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252

PuMP
Start date: May 1, 2024
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open label study designed to assess the safety and tolerability of the oncolytic herpes simplex virus 1 (oHSV1) study drug, MVR-C5252, administered intratumorally by convection-enhanced delivery (CED) in patients with recurrent high-grade glioma. Once the safety and maximum tolerated dose (MTD) is established in the dose escalation portion of the trial, a dose expansion cohort at the recommended phase 2 dose (RP2D) in patients with isocitrate dehydrogenase (IDH) wildtype recurrent glioblastoma (GBM) will evaluate preliminary efficacy of the study drug.

NCT ID: NCT02416999 Not yet recruiting - Clinical trials for Recurrent High-grade Glioma

Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

Start date: May 2015
Phase: N/A
Study type: Interventional

This study is to evaluate the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.

NCT ID: NCT02333513 Not yet recruiting - Clinical trials for Recurrent High-grade Glioma

A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation

Start date: February 2015
Phase: N/A
Study type: Interventional

This trial is aimed at evaluating the safety and effectiveness of PCV chemotherapy in patients with recurrent high-grade glioma with IDH1/2 mutation.